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The chikungunya virus (CHIKV), an arthritogenic alphavirus, has caused explosive epidemics involving
millions of cases. Globally expanding pandemics involving CHIKV and post-CHIKV rheumatic disorders
are increasing public health concerns. However, no antiviral interventions or vaccines to control CHIKV
infection have yet been approved. Although suramin has been possess anti-CHIKV activity in vitro,
whether suramin has anti-CHIKV activity in vivo remains unknown. This study aimed to determine
whether suramin treatment could ameliorate CHIKV-induced arthritis in a C57BL/6 mice model.
C57BL/6 mice were infected with CHIKVs to evaluate anti-CHIKV activities of suramin in terms of
histopathology, viral burden and disease score. Not only did suramin treatment substantially decrease
viral loads, but it also signiﬁcantly ameliorated acute foot lesions in mice. In addition, suramin treatment
markedly restores cartilage integrity and reduces the number of IHC positive chondrocyte in mice
infected with CHIKV strains 0810bTw and 0706aTw. This in vivo study highlights the potential ability of
suramin to treat CHIKV infection in clinical settings.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chikungunya virus (CHIKV), an enveloped plus-stranded RNA
virus, belongs to the genus alphavirus of family Togaviridae. CHIKV
is an arbovirus transmitted by infected Aedes mosquito species. In
human, symptoms of CHIKV infection include fever, rash, myalgia
and persistent incapacitating arthralgia. For example, in 2005, a
CHIKV outbreak on Reunion Island caused more than 60% of CHIKV
patients to experience arthralgia during the 3 years that followed
acute infection (Schilte et al., 2013). Evidence has also suggested
that CHIKV infection can lead to rheumatic disorders (Bouquillard
and Combe, 2009; Brighton et al., 1983; Javelle et al., 2015; Miner
et al., 2015; Zeana et al., 2016), such as chronic arthritis that
mimics rheumatoid arthritis (RA), a condition which can last from
weeks to years. Moreover, previous research has found that 5.6% of
CHIKV patients suffered persistent joint pain and stiffness, and
these patients retained very high CHIKV antibody titers three yearsMedicine, National Defense
x19810.
.-C. Lin).
B.V. This is an open access article uafter disease onset (Brighton et al., 1983). Finally, two studies have
observed CHIKV patients suffering from erosive arthritis, which
was induced by post-infection with arthritogenic alphaviruses
(Chaaithanya et al., 2014; Manimunda et al., 2010). Subtle genetic
change in CHIKV E1-A226V has been associated with an increase of
the vector competence for Ae. albopictus, but not Ae. aegypti
(Schuffenecker et al., 2006; Tsetsarkin et al., 2007; Vazeille et al.,
2007), and expanding global pandemics of CHIKV are causing an
increase in public health concerns. For example, in Latin America, it
is estimated that 0.4 million patients will develop post-CHIKV
chronic inﬂammatory rheumatism (Rodriguez-Morales et al.,
2015). Currently, there are no approved vaccines and no antiviral
interventions to control CHIKV-induced rheumatologic disease.
Therefore, advances in antiviral research could greatly beneﬁt the
management of CHIKV infections.
Despite signiﬁcant gaps in the clinical literature, previous
studies found that treating CHIKV-infected mice with bindarit, an
inhibitor of MCP-1 synthesis, reduced the severity of CHIKV-
induced bone loss and musculoskeletal tissue inﬂammation
(Chen et al., 2015; Rulli et al., 2011). Furthermore, synergetic anti-
CHIKV effects of Mefenamic acid and ribavirin have beennder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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CHIKV activity of phosphorodiamidate morpholino oligomers (Lam
et al., 2015). T-705 (Favipiravir; 6-ﬂuoro-3-hydroxy-2-
pyrazinecarboxamide), a nucleobase mimetic, reduces brain infec-
tion and mortality rate by more than 50% in CHIKV-infected AG129
mice (Delang et al., 2014). In CHIKV- or Ross River virus (RRV)-
infected mice, pentose polysulfate treatment was reported to
decrease acute signs of foot swelling and inﬂammation (Herrero
et al., 2015). Finally, the anti-CHIKV activity of MBZM-N-IBT (1-
[(2-methylbenzimidazol-1-yl) methyl]-2-oxo-indolin-3-ylidene]
amino] thiourea), a molecular hybrid of 2-methyl benzimidazole
and isatin-b-thiosemicarbazone, have been found to target the
early and late stages of CHIKV infection (Mishra et al., 2016). Sur-
amin is an anti-parasitic drug, used to treat human sleeping sick-
ness caused by trypanosomes and onchocerciasis (McGeary et al.,
2008). Suramin has been shown to inhibit CHIKV entry, trans-
mission and replication in vitro (Albulescu et al., 2015; Ho et al.,
2015). Moreover, there is evidence to suggest that suramin in-
duces immunosuppressive effects by inhibiting CD40/CD154
(Margolles-Clark et al., 2009), purinergic receptor bindings (Liu
et al., 2014) and TNF-a/TNF-a receptor binding (Mancini et al.,
1999).
A mouse model to evaluate therapeutic agents (Fox et al., 2015;
Herrero et al., 2015; Jin et al., 2015; Pal et al., 2013; Rulli et al., 2011)
and vaccines (Garcia-Arriaza et al., 2014; Hallengard et al., 2014;
Piper et al., 2013; Wang et al., 2011) has been developed to study
CHIKV infection. Furthermore, several studies have evaluated the
antiviral activities of various drugs by subcutaneously injecting
CHIKV into immuno-competent C57BL/6 mice via footpad induced
arthritis (Gardner et al., 2010; Morrison et al., 2011; Rulli et al.,
2011), and others have used this mouse model to compare patho-
genesis among CHIKV strains (Ashbrook et al., 2014). However, a
mouse model has not been used to investigate the effects of sur-
amin on CHIKV infection in detail.
In this study, we exploited the C57BL/6 mice model to investi-
gate the anti-CHIKV activities of suramin in vivo. Speciﬁcally,
pathogenic proﬁles of 3 clinical isolates were observed in CHIKV-
infected mice. Treatment with suramin was found to reduce viral
burdens, alleviate CHIKV-induced mice foot swelling and decrease
histopathologic lesions. Taken together, our ﬁndings suggest that
suramin has potential protective effects against CHIKV infection
in vivo.2. Materials and methods
2.1. Viruses, cells and chemical
BHK-21 cells were cultured in Dulbecco's Modiﬁed Eagle Me-
dium (DMEM) with 5% heat inactivated fetal bovine serum (FBS)
and antibiotics under 5% CO2 at 37 C. C6/36 cells were cultured in
RPMI-1640 medium with 10% heat inactivated FBS and antibioticsFig. 1. Schedule detailing CHIKV inoculation, suramunder 5% CO2 at 28 C. CHIKV strains 0611aTw (Singapore/
0611aTw/2006/FJ807896), 0810bTw (Malaysia/0810bTw/2008/
FJ807899) and 0706aTw (Indonesia/0706aTw/2007/FJ807897)
were ampliﬁed and titers were determined by conducting a plaque
assay in BHK-21 cells (Ho et al., 2015). Suraminwas purchased from
Sigma-Aldrich (catalog #S2671).
2.2. Ethics statement
All animals were handled in strict accordance with good animal
practice as deﬁned by the Council of Agriculture, Executive Yuan,
Taiwan R.O.C. Protocol involving animals were approved by the
Institutional Animal Care and Use Committee of the Institute of
Preventive Medicine, National Defense Medical Center. Taiwanese's
regulations classify CHIKV is as a bio-agent in Risk Group 3. All
studies with viable CHIKV were performed in certiﬁed BSL-3 lab-
oratories. Biosafety protocols used by this study were approved by
the Institutional Biosafety Committees of the Institute of Preven-
tion Medicine, National Defense Medical Center.
2.3. CHIKV challenge study
To investigate the anti-CHIKV activities of suramin in vivo,
C57BL/6JNarl (B6) mice of speciﬁc pathogen-free condition were
purchased from the National Laboratory Animal Center (P.O. Box 1-
86 Nankang, Taipei City 11529, Taiwan R.O.C.). All mice were female
and aged 4 weeks. There were 35, 40 and 5 mice (n ¼ 5 per group)
used for testing anti-CHIKV activities of suramin in viral strains,
dose/time related and foot swelling over time assays, respectively.
A schedule detailing incubation with CHIKV, treatment with sur-
amin and examination of mice is provided in Fig. 1. Suramin was
diluted in normal saline, and indicated doses were administered at
4 h pre-infection, 1 day post-infection or/and 3 day post-infection
(dpi) via the intraperitoneal (ip) route. Speciﬁcally, each dose
comprised 0, 0.25, 0.5, 1 or 2 mg suramin. Mice were subcutane-
ously (s.c.) inoculated with 50 ml CHIKV (105 pfu) via the ventral
side of the right hind foot, towards the ankle. Submandibular blood
was collected at 2 dpi for viremia analysis. The height and width of
the metatarsal area of hind feet were measured using Kincrome
digital verniercalipers at 7 dpi. After mice were euthanized via an
overdose of isoﬂurane anesthesia followed by cervical dislocation.
Hind feet from scariﬁed mice were collected for histopathologic
analysis at 7 dpi.
2.4. Histopathology and immunohistochemistry (IHC)
Hind feet were ﬁxed in 10% buffered formalin (Electron Micro-
scopy Sciences), decalciﬁedwith 15% EDTA in 0.1% phosphate buffer
over 10 days and embedded in parafﬁn wax. We cut 3-mm-thick
sections from the wax and stained these sections with
hematoxylin-eosin or Safranin-O/Fast Green dye. Histologicalin treatment and examination of C57BL/6 mice.
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system (Romas et al., 2002). 0 ¼ no inﬂammation, 1 ¼ minimal
inﬂammatory inﬁltration, 2 ¼ mild inﬁltration, 3 ¼ moderate
inﬁltration with moderate edema, 4 ¼ marked inﬁltration with
marked edema, 5 ¼ severe inﬁltration with edema (n ¼ 5 feet per
group). For immunohistochemistry analysis, the 3-mm-thick sec-
tions were deparafﬁnized with xylene and rehydrated in serial di-
lutions of ethanol. Antigens were retrieved by immersing tissue
sections into epitope retrieval buffer. Endogenous peroxidase ac-
tivity was blocked with 3% hydrogen peroxide solution, and slides
were incubated with protein blocking buffer for 10 min. Subse-
quently, tissue sections were incubated with rabbit anti-CHIKV E2
sera (1/1000) (Kuo et al., 2011) at room temperature for 30 min,
washed in TBST at pH 7.0, and developed using the Polink-2 HRP
Plus Rabbit DAB Detection System (Golden Bridge International,
Inc.) according to manufacturer's protocol. All pictures (six pictures
from 2 feet per group) were taken under the same lighting and
magniﬁcation parameters with an Olympus BX43 microscope. The
intensity of CHIKV E2 signals was measured using ImageJ software.
For this, color deconvolution was used to separate DAB stains
(CHIKV E2 signals) from hematoxylin stain (whole tissue area).
Speciﬁcally, each picture was converted to grayscale and adjusted
using the Thresholding method, and the areas of DAB and hema-
toxylin stains were measured (Analyze/Measure). E2 expression
score of CHIKV was calculated by dividing the total tissue area by
the positively stained area (Safadi et al., 2010).
2.5. Measurements of viremia
Sera from submandibular blood of CHIKV-infected ormockmice
(i.e. mice infected with PBS containing 10% culture medium) were
stored at 70 C. In a 96-well plate, 3  105 C6/36 cells per well
were inoculated with 100 ml medium containing a serial 10-fold
diluted blood sample in duplicate. At 3 dpi, ﬁxed cells were
stained with rabbit anti-CHIKV E2 serum (1/100) (49) and Alex 488
goat ant-rabbit IgG (1/500) (Invitrogen, Molecular Probes, Carlsbad,
CA). Viral loads were expressed as CCID50/ml of serum (Gardner
et al., 2010).
2.6. Statistical analysis
All statistical analyses were performed using GraphPad Prism
version 6.0.1 software. Differences between the mock-treated
group and the suramin-treated group were assessed using the
student's t-test. P values are mean ± SD for n ¼ 5 or 6.
3. Results
3.1. Treatment with suramin decreases viral burden and foot
swelling in CHIKV-infected mice
To assess the anti-CHIKV activity of suramin in vivo, mice were
infected with one of the following CHIKV strains: 0611aTw,
0810bTw or 0706aTw. Several previous studies have found that the
viremia peak of CHIKV-infected mice is at 2 dpi (Garcia-Arriaza
et al., 2014; Gardner et al., 2010; Poo et al., 2014a, 2014b; Wang
et al., 2011). Infected mice were treated with either 2 mg suramin
or mock at 4 h pre-infection, 1 dpi and 3 dpi (Fig. 1). In the current
study, viral loads in sera of mock-treated mice infected with the
0810bTw, 0611aTw and 0706aTw CHIKV strains at the 2 dpi peak
were 5.8, 3 and 4.2 Log10 CCID50/ml, respectively (Fig. 2A). To par-
allel, viral titers of suramin-treated sera after received two doses
(pre 4 h and 1 dpi) were 5, 2.5 and 3.8 Log10 CCID50/ml for 0810bTw,
0611aTw and 0706aTw strains, respectively. Therefore, suramin
treatment signiﬁcantly decreased in viral loads in 0810bTw-infected mice.
In order to determine the peak of foot swelling induced by
CHIKV infection, we quantiﬁed foot swelling over time in 0810bTw-
infected mice (Fig. S1). Maximum foot swelling occurred at 7 dpi,
which corresponds to results obtained by previous studies
(Gardner et al., 2010; Poo et al., 2014a). To further characterize the
therapeutic effects of suramin treatment on CHIKV infections, foot
swelling and histopathologic lesions at peak disease (7 dpi) were
examined for both suramin-treated and mock-treated mice. As
shown in Fig. 2B, paw volumes of mock-treated mice infected with
0810bTw, 0611aTw and 0706aTw were 12.28 ± 0.2, 8.13 ± 0.11 and
10.98 ± 0.12 mm2, respectively. Corresponding to the result of
viremia, strains 0810bTw and 0706aTw caused swelling and edema
which were much more severe than that associated with the
0611aTw strain. Interestingly, paw volumes of suramin-treated
mice infected with strains 0810bTw (7.85 ± 0.27 mm2), 0611aTw
(7.22 ± 0.24mm2) and 0706aTw (8.42 ± 0.16mm2) decreased by 36,
11 and 23% compared to their mock-treated counterparts.
Furthermore, suramin treatment decreased the size of hind feet in
CHIKV-infected mice to nearly that of control (7.13 ± 0.07 mm2) at
7 dpi. No detectableweight loss was observed inmock-treatedmice
and control mice (Fig. 2C), but suramin treatment resulted in sig-
niﬁcant weight loss. However, signiﬁcant weight gains in suramin-
treated mice have been observed at 9 dpi (data not shown);
therefore, the weight loss effect of suramin treatment was tem-
porary. Taken altogether, our results suggest that suramin treat-
ment substantially reduces viral burden and also alleviates CHIKV-
induced foot swelling in mice.
3.2. Treatment with suramin alleviates musculoskeletal lesions in
CHIKV-infected mice
To conﬁrm the effects of suramin treatment in foot swelling in
CHIKV-infected mice, histological analysis was conducted to
examine the histopathological proﬁle in infected feet. Microscopic
results at maximum foot swelling (7 dpi) showed that the feet of
0706aTw- and 0810bTw-infected mice had extensive acute lesions
including inﬂammatory inﬁltrates, subcutaneous edemas, ﬁbrinous
exudates and periostitis (Fig. 3A). Conversely, infection with the
0611aTw strain only induced mild inﬂammatory inﬁltrates. Control
mice did not show any inﬂammatory inﬁltrates. Interestingly, sur-
amin treatment led to a marked reduction in acute foot lesions of
mice infected with all three strains of CHIKV compared to mock-
treated mice, and histopathological scores revealed that suramin
treatment led to a statistically signiﬁcant reduction in inﬂamma-
tory inﬁltrates (Fig. 3C).
To further conﬁrm the effects of suramin treatment on viral
infection, IHC was performed to detect the expression of viral an-
tigen (E2 glycoprotein) in infected tissues. The speciﬁcity of IHC is
illustrated in Fig. S2. In the feet of CHIKV-infected mice, IHC signals
were mainly observed in macrophages, epithelial cells, bone cells,
chondrocytes, periosteum and muscle cells. Similar to the histo-
logical inﬂammation scores, a more intense E2 signal was detected
in mock-treated mice infected with either 0706aTw or 0810bTw
than in mock-treated mice infected with 0611aTw (Fig. 3B and D).
However, suramin treatment uniformly prohibited the expression
of E2 glycoprotein in hind foot tissues of infected mice (Fig. 3B and
D). Therefore, the IHC analysis conﬁrms that suramin treatment can
signiﬁcantly inhibit CHIKV replication in vivo.
In mice models, RRV and CHIKV infections cause the destruction
of cartilage including through the depletion of matrix proteoglycan
(Herrero et al., 2015; Poo et al., 2014a). Thus, we sought to further
elucidate the therapeutic effects of suramin in CHIKV-infected mice
by evaluating cartilage integrity. At 7 dpi, IHC and histological
evaluations of joint sections stained with Safranin O-fast green dye
Fig. 2. Evaluation of anti-CHIKV activity of suramin in mice. Mice were inoculated with the following CHIKV strains via the right hind foot: 0611aTw, 0810bTw or 0706aTw. For all
CHIKV strains, mice were subcutaneously (s.c.) inoculated with 50 ml CHIKV (105 pfu) via the ventral side of the right hind foot. To establish mock treatment groups, some CHIKV-
infected mice were administered with 100 ml normal saline (0810bTw, 0611aTw and 0706aTw). Treatment groups comprised CHIKV-infected mice which were administered the
indicated dose (0810bTw þ suramin, 0611aTw þ suramin and 0706aTw þ suramin) at 4-h pre-infection, 1 dpi and/or 3 dpi by the ip route. The height and width of the metatarsal
area of right hind feet were measured using Kincrome digital verniercalipers at 7 dpi. For control mice, 50 ml diluted medium (1/10) was injected into right hind feet, and treatment
involved administering 100 ml normal saline via the ip route at 4-h pre-infection, 1 dpi and 3 dpi. P values were determined using the Student's t-test. A. Effects of suramin treatment
on viral burdens. Viremia measurements for CHIKV-infected mice were determined using the CCID50 method at 2 dpi. Each symbol represents an individual sample. Bars show the
mean ± SEM. B. Effect of suramin treatment on CHIKV-induced foot swelling. Each symbol represents an individual sample. Bars show the mean ± SEM. C. Average weight of CHIKV-
infected mice in mock-treated and suramin-treated groups. Body weight was measured at 0, 2, 4, 6 and 7 dpi. Values denote average weight ± SD for; *p < 0.05, **p < 0.01 and
***p < 0.001 compared to the control group at 7 dpi.
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severe cartilage destruction (Fig. 4A) and a great abundance of E2-
positive chondrocytes than did the 0611aTw strain (Fig. 4B).
However, suramin treatment markedly restored cartilage integrity
and reduced the number of IHC positive chondrocyte in mice
infected with 0810bTw and 0706aTw.
Taken together, the results described in this section clearly
demonstrate that suramin treatment decreases the infectivity of
CHIKV and ameliorates CHIKV-induced arthritis in C57BL/6 mice.3.3. Dose- and time-related evaluations of suramin treatment
In this study, the most signiﬁcant therapeutic effects of suramin
treatment were observed in 0810bTw-infected mice. We therefore
used the CHIKV0810bTw strain to perform dose- and time-related
assays. For the dose-related assay, infected mice were treated with
three-doses of two-fold serial diluted suramin (2, 1, 0.5 or 0.25 mg)
at 4 h pre-infection, 1 dpi and 3 dpi. For the time-related assay,
infected mice were administered a single dose of 2 mg suramin at
4 h pre-infection (pre 2mg), or post-treatedwith two doses of 2mg
suramin at 1 dpi and 3 dpi (post 2 mg). We observed that suramin
variably decreased viremia in dose- and time-related assays
(Fig. 5A). Foot swelling under treatment with 2 mg(7.85 ± 0.27 mm2), 1 mg (8.59 ± 0.28 mm2), 0.5 mg
(9.83 ± 0.24 mm2), 0.25 mg (11.05 ± 0.3 mm2), pre 2 mg
(9.31 ± 0.16 mm2) and post 2 mg suramin (8.94 ± 0.13 mm2) was
reduced by 34, 28, 18, 8, 22 and 25%, respectively, compared to
mock-treated mice (11.98 ± 0.36 mm2) (Fig. 5B). Interestingly, a
single dose of 2 mg suramin treatment at 4 h pre-infection (pre
2 mg) led to a markedly reduced viral burden and signiﬁcantly
decreased foot swelling. Results from average weight monitoring
(Fig. 5C), showed dose-dependent weight loss in suramin-treated
mice. Notably, all dose- and time-dependent treatments of sur-
amin substantially reduced viral burden and disease score in
CHIKV-infected mice.4. Discussion
Since the 2005 CHIKV outbreak that occurred on Reunion Island,
CHIKV disease incidence and persistent CHIKV-induced RA-like
symptom have been a burden on public health. Due to a lack of
speciﬁc anti-CHIKV drugs, the nosological approach is presently the
only treatment option for post-CHIKV rheumatic disorders.
Currently, alphaviral arthritides can be relieved with analgesics
and/or nonsteroidal anti-inﬂammatory drugs (NSAIDs) (Jaffar-
Bandjee et al., 2010; Mylonas et al., 2002; Suhrbier and La Linn,
Fig. 3. Effect of suramin treatment on CHIKV-induced histopathological proﬁles. A. Effect of suramin treatment on CHIKV-induced inﬂammation. Right hind feet collected at 7 dpi
were ﬁxed, decalciﬁed and stained with hematoxylin-eosin. Boxed areas in upper panels represent the same tissue as that shown in the bottom panels, albeit at a higher resolution
(200 versus 50 magniﬁcations). The foci of myositis are delineated by black arrows. Periostitis in CHIKV-infected mice is indicated by white arrows with inﬂammatory cells
present in the tendon capsule. (Bars: 100 mm). B. Effects of suramin treatment on the expression of viral E2 antigen in the feet of CHIKV-infected mice. Effects were determined by
conducting an immunohistochemical analysis of E2 glycoprotein in feet from suramin-treated or mock-treated mice at 7 dpi. Boxed areas in upper panels present the same tissue
section as that shown in bottom panels, albeit at a higher resolution (800 magniﬁcation). The foci of E2 glycoprotein are indicated by black arrows. C. Histological evaluation of
suramin treatment on CHIKV-induced inﬂammation. The evaluation was conducted according to the following scoring system: 0 ¼ no inﬂammation, 1 ¼ minimal inﬂammatory
inﬁltration, 2 ¼mild inﬁltration, 3 ¼moderate inﬁltrationwith moderate edema, 4 ¼marked inﬁltrationwith marked edema, 5 ¼ severe inﬁltrationwith edema. Values present the
mean ± SEM. P values were determined using the Student's t-test. D. Intensity of CHIKV E2 signals in the feet of CHIKV-infected mice. Values presented in the graphs denote
mean ± SEM (n ¼ 6).
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arthritis with NSAIDs alone or conjugation with steroid leads to a
positive clinical response (Rosario et al., 2015). CHIKV-induced RA-
like arthritis can also be efﬁciently treated with methotrexate of
disease-modifying anti-rheumatic drug (DMARD) therapy (Chopra
et al., 2008; Javelle et al., 2015). However, the immunosuppressive
activities of the aforementioned drugs should be considered during
the acute phase of CHIKV infection.
Suramin shows a broad-spectrum of antiviral activities in vitro.
Our study has found that suramin blocks the entry and egress of
CHIKV infection (Ho et al., 2015). In this study, we employed a
C57BL/6 mouse model to investigate the pathogenesis of CHIKV
infections as well as the efﬁcacy of suramin treatment against this
disease in vivo. Results showed that viral loads of CHIKV strains0810bTw, 0611aTw and 0706aTw strains during peak viremia
(2 dpi) were 5.8, 3 and 4.2 Log10 CCID50/ml, respectively (Fig. 2A).
Infection with the three strains of CHIKV also induced (with vary
degrees of severity) foot swelling, myositis, synovitis, cartilage
destruction, periostitis and perivasculitis (Figs. 2B and 3A, C). Gross
and histological results were correlated with viral burden, as evi-
denced by ﬁndings fromvirus titration and IHC (Figs. 2A and 3B, D).
In humans, CHIKV viral antigens have previously been detected in
arthritic capsules, skeletal muscle and dermis (Couderc et al.,
2008). Furthermore, human muscle satellite cells have been iden-
tiﬁed as the target of CHIKV (Ozden et al., 2007). In this study,
CHIKV E2 was detected in inﬂammatory inﬁltrates, epithelial cells,
bone cells, chondrocytes, periosteum and muscle cells in CHIKV-
infected feet (Figs. 3B and 4B), which corresponds to
Fig. 4. Effect of suramin treatment on CHIKV-induced cartilage damage. A. Safranin-O/Fast Green staining to evaluate CHIKV-induced cartilage destruction in mock-treated or
suramin-treated mice at 7 dpi. Proteoglycans (in red) are denoted by black arrows. B. Immunohistochemical analysis to detect E2 glycoprotein expression in cartilage from mock-
treated or suramin-treated mice at 7 dpi. The foci of E2 glycoprotein are indicated by black arrows. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
Fig. 5. Dose- and time-related evaluations of suramin treatment in CHIKV-infected mice. Mice were inoculated with 105 pfu of CHIKV strain 0810bTw via the right hind foot. For the
dose-related assay, CHIKV infectedmicewere treatedwith three doses of 0, 2,1, 0.5 or 0.25mg of suramin at 4 h pre-infection,1 dpi and 3 dpi. For time-related assay, we compared the
effectiveness of twotreatment regimens: pre-treatment (at 4hpre-infection; pre2mg) andpost-treatment (at 1dpi and3dpi; post 2mg). A * symbol indicates that differences between
mock-group and treatment-groupmice were signiﬁcant. A. Dose- and time-related evaluations of suramin treatment on viral burdens. Viremiameasurements of CHIKV-infectedmice
were determinedusing the CCID50method at 2 dpi. B. Dose- and time-related evaluations of suramin treatment onCHIKV-induced foot swelling. The height andwidth of themetatarsal
area of right hind feet were measured using Kincrome digital verniercalipers at 7 dpi. Control mice were injected with 50 ml diluted medium (1/10) via the right hind foot, and were
treatedwith 100 ml normal saline at 4 h pre-infection,1 dpi and 3 dpi via the ip route. C. Averageweight of CHIKV-infectedmice in dose- and time-related evaluations. Bodyweightwas
measured at 0, 2, 4, 6 and 7 dpi. Values denote average weight ± SD; *p < 0.05, **p < 0.01 and ***p < 0.001 compared to the group that received 0 mg at 7 dpi.
S.-C. Kuo et al. / Antiviral Research 134 (2016) 89e9694characteristics of cell and tissue tropisms associated with CHIKV
infection in humans. Analysis of cartilage damage showed that
infection with the 0810bTw strain induces obvious proteoglycandepletion and abundant E2-positive chondrocytes. Therefore, in
mice, the pathogenic proﬁles of CHIKV strain 0810bTw, 0611aTw
and 0706aTw were correlated with their virulence.
S.-C. Kuo et al. / Antiviral Research 134 (2016) 89e96 95Suramin treatment reduced viral loads in 0810bTw-, 0611aTw-
and 0706aTw-infectedmice whichmight due to suramin treatment
to block CHIKV entry and egress (Figs. 2A and 5A) (Ho et al., 2015).
However, 0810bTw was the most sensitive strain to suramin
treatment among the 3 CHIKV isolates in vivo which corresponded
to their EC50 activities in vitro (Ho et al., 2015). Suramin treatment
also ameliorated foot swelling and reduced inﬂammatory inﬁltra-
tion, which corresponded to reduced viremia and viral antigen
expression in infected tissues. In addition, results from Safranin-O/
Fast Green staining and IHC analysis showed that suramin treat-
ment restored the integrity of foot cartilage in 0810bTw-infected
mice (Fig. 4A and B). Furthermore, we found that suramin induces a
dose-dependent reduction in foot swelling in CHIKV 0810bTw-
infected mice (Fig. 5AeB), and the vary degrees of decreased
viremia that was detected in suramin-treated mice further
conﬁrmed therapeutic effects of this drug. In the time-related
assay, a single dose of 2 mg suramin (at 4 h pre-infection) or
double doses of 2 mg suramin (at 1 dpi and 3 dpi) signiﬁcantly
decreased disease score and viremia compared to mock-treated
mice. Due to the limitations of viremia determination at 7 dpi
(feet swelling measurement), we were only able to detect viremia
of three strains at peak (i.e. 2 dpi; when mice had only received 2
doses of suramin), which may not fully reﬂect the anti-CHIKV ac-
tivity of suramin. Nevertheless, the expressions of the viral E2
protein (which provides further evidence of viral load), detected by
IHC at 7 dpi (after mice received 3 doses of suramin), was signiﬁ-
cantly reduced. This results showing reduced foot swelling,
inﬂammation and cartilage damage, indicate that suramin has
therapeutic effects on CHIKV-infected mice. Dose-dependent
weight loss also was observed in dose- and time-related evalua-
tions of suramin treatment. Importantly, a single pre-treatment of
2mg suramin at 4 h pre-infection optimized therapeutic effects and
weight maintenance. Taken together, our ﬁndings clearly demon-
strate the anti-CHIKV activities of suramin in vivo. The immuno-
suppressive effects of suramin have also been found to alleviate
collagen induced arthritis in rat (Sahu et al., 2012) and acute
rejection of lung allograft in mice (Liu et al., 2014). Therefore, the
immunosuppressive effects of suramin may have partly contrib-
uted to the relief CHIKV-induced arthritis in mice.
The highest EC50 of strain 0611aTw in U2OS cell was 71.5 mM
(59.6 þ 11.9 mM; 102 mg/ml) (Ho et al., 2015), and the average body
volume was 19 ml (average body weight/average body
density ¼ 20 g/1.05) (Amaro et al., 2014). In order to test the
maximum anti-CHIKV activity of suramin in vivo, a 2 mg dose (2mg
suramin/19 ml/mice ¼ 105 mg/ml) was ﬁrst administered. Some
evidence has suggested that a 2 mg dose is toxic in mice (Yoneda
et al., 1995); however, our results showed that 2 mg suramin
signiﬁcantly reduces E2 intensity, pathological scores, and transient
weight loss. In addition, viral load was signiﬁcantly reduced after
mice were treated with two doses of 0.5 mg suramin (Fig. 5A;
30 mg/kg). A higher dose of 50 mg suramin/kg has previously been
used to evaluate the anti-enterovirus 71 activity of suramin in mice
(Ren et al., 2014). In the time-related assay, we found that pre-
treating mice with a 2 mg dose was most effective at reducing
viral load. Therefore, ﬁndings from this study suggest that suramin
may have both prophylactic and therapeutic advantages for CHIKV
treatment. Future studies could beneﬁt CHIKV research by inves-
tigating the dose dependent effects of suramin pretreatment.
Identifying the minimal pre-treatment dose should help further
elucidate the prophylactic effects of suramin.
In conclusion, our ﬁndings clearly demonstrate that suramin
treatment decreases viral burden and helps mitigate acute disease
symptoms in CHIKV-infected mice. This preclinical study provides
evidence to support clinical trials which investigate the feasibility
of using suramin to treat chikungunya Fever.Conﬂicts of interest
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